Business
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
LYON, France, May 13, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2025 and provided corporate update.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/30c4f797e5e98bbf82e714e5197fba45"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yVVqUyxx.d_ecMBX7ILatg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/30c4f797e5e98bbf82e714e5197fba45","width":480,"height":256}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"TWYMEEG® consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma’s latest guidance3","length":174,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sumitomo Pharma forecast for TWYMEEG®’s FY 20254 of JPY 11.2 billion (EUR 69,4 million2), representing a 47% increase over FY 2024 sales","length":136,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In FY2024, Poxel started receiving 10% royalties on TWYMEEG® net sales, and from FY2025 5 anticipates receiving escalating double-digit royalties and additional sales-based payments upon achievement of contractual sales thresholds","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Regulatory approval on April 8, 2025, by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enabling Sumitomo Pharma to immediately start promoting the use of TWYMEEG® (Imeglimin) in type 2 diabetic patients with moderate to severe renal impairment","length":260,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ongoing discussions with 1/ creditors to ensure continuity of the Company’s operations and 2/ potential partners for the development of pipeline products","length":153,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":953,"olType":false},{"type":"text","content":"LYON, France, May 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the ...